Registry of procalcitonin-guided antibiotic therapy in patients with lower respiratory tract infections outside of study conditions: ?Pro-REAL? - a ?real-life survey
Completed
- Conditions
- Respiratory tract infectionsInfections and Infestations
- Registration Number
- ISRCTN40854211
- Lead Sponsor
- BioMérieux (France)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 1200
Inclusion Criteria
1. Both males and females, age >18
2. Lower respiratory tract infection (at least one respiratory symptom [cough, sputum production, dyspnea, tachypnea, pleuritic pain]) PLUS
3. One of the following auscultatory finding or sign of infection:
3.1. Core body temperature >38°C or <36°C
3.2. Shivers
3.3. Leukocyte count >10 g/L or <4 g/L cells
Exclusion Criteria
Does not meet inclusion criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Duration of antibiotic treatment<br><br>All primary and secondary outcome measures will be assessed by a telephone interview 30 days after the start of the treatment.
- Secondary Outcome Measures
Name Time Method 1. Adherence to procalcitonin algorithm<br>2. Adverse medical outcomes (complications, mortality, relapse, intensive care unit [ICU] admission)<br>3. Antibiotic side effects<br>4. Length of hospital stay<br>5. Differences between procalcitonin (PCT) levels measured by KRYPTOR® and VIDAS®<br><br>All primary and secondary outcome measures will be assessed by a telephone interview 30 days after the start of the treatment.